Atopic Dermatitis

The study addresses safety concerns related to the risk of keratinocyte carcinoma for patients with atopic dermatitis.

The FDA will be working over the next few months to ensure tralokinumab is efficient for atopic dermatitis.

An expert explains differences between tralokinumab and other popular agents for atopic dermatitis.

The data from the phase 3 AD Up trial add to existing knowledge of the efficacy and safety of upadacitinib for patients with atopic dermatitis.

Kim Kjøller, MD, breaks down the findings from ECZTRA1, 2, and 3.

Kim Kjøller, MD, discusses how tralokinumab can be used for the treatment of atopic dermatitis.

Subcutaneous injections of nemolizumab in addition to topical agents result in a greater reduction in pruritus than placebo plus topical agents.

The FDA is allowing the pen to be used for the treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis (CRSwNP) patients at least 12 years old.

The newest indication for the add-on biologic grants it use in children aged 6-11 years old with moderate to severe, uncontrolled atopic dermatitis.

A systematic review and meta-analysis show the systemic therapies, as well as a couple investigational biologics, may be superior.

New pivotal phase 3 findings support an upcoming sBLA for the IL4 and IL13-targeting agent.

Lisa Stein Gold, MD, of Henry Ford Hospital discusses promising phase 2 data for a new PDE4 inhibitor.

New data evidences yet another IL-13 targeting biologic for atopic dermatitis.

The Ready, Set, Food! co-founder discusses how research and federal advisory shapes parental understanding of immunotherapy and food allergy prevention.